A clinical team has spearheaded the use of CAR-T cell therapy for blood cancers. The researchers recently treated the first ...

Ernexa Therapeutics embarks on new strategic direction, shifting the company’s focus from delivering a cell therapy platform to prioritizing product development New tagline to emphasize the company’s ...

Stem cell therapy has emerged as a groundbreaking treatment option for corneal injuries, offering hope to individuals ...

Kennedy Jr. hosted a roundtable on reducing regulations on stem cells earlier this month, experts have raised concerns about ...

Since 2019, the company has specialized in developing, manufacturing, and releasing autologous and allogeneic cell therapy products for early- to mid-stage clinical trials, and has evolved into an ...

The global CAR T-cell therapy market is projected to grow from USD 2.7 billion in 2025 to over USD 27.5 billion by 2033, reflecting a robust CAGR of 26.2%.

A new study published in The Lancet Haematology journal says that an indigenously developed gene therapy for certain blood ...

This approval was followed by Takeda Pharmaceuticals’ Alofisel (darvadstrocel), which received approval from the European Medicines Agency in 2018 and from Japan’s Pharmaceuticals and Medical Devices ...

The injection 'talicabtagene autoleucel' is now approved in India, "available for USD 30,000," which is "less than one-tenth of the price of other approved CD19 CAR T-cell therapy products ...

As a BCMA-targeting CAR T-cell therapy, CARVYKTI addresses a high unmet need in relapsed or refractory multiple myeloma patients. With promising clinical efficacy, durable responses, and growing ...

The study looked at patients with leukaemia, which occurs in bone marrow, and lymphoma, which affects the lymphatic system.